VAKCINA

Mór Thököly wrote:

bemty wrote:SRBIJA!!

da, i ovde trenutno daju samo prioritetnima... ali daju i deci. otkrili su da su skolska deca najveci prenosioci, pa uredno idu po skolama i daju im nazalni sprej s vakcinom. ne znam kad cu ja doci na red kao neprioritetna, ali trebalo bi u nekom momentu i to da se desi.

Cega, virusa? Ma nemoguce...

Brnabić: Srbija će [najverovatnije] tek u drugoj polovini sledeće godine imati na raspolaganju vakcine protiv COVID-19.
...
Ja sam juče  imala razgovor sa jednim od proizvođača vakcina koji će uskoro biti registrovan mislim i pri EU, do koga smo jedva došli i koji je rekao, da, možete da dobijete vakcinu u 4. kvartalu 2021. Do tada smo već prodali sve naše vakcine.

Sve zdravstvene ustanove dobile su "nalog" Hrvatskog zavoda za javno zdravstvo po kojem do ponedjeljka moraju županijskim zavodima dostaviti popis svojih djelatnika koji se namjeravaju cijepiti protiv covida-19 kako bi se na vrijeme mogao napraviti detaljan plan cijepljenja.
...
Po svemu sudeći, zdravstveni djelatnici koji se odluče na cijepljenje cijepit će se u svojim ustanovama koje trebaju odrediti osobe za procjepljivanje kao što se to čini i kod cijepljenja za gripu. Naime, oni, kao i korisnici i zaposlenici domova za starije, u planu su za cijepljenje u prvoj fazi. Nakon toga slijedi druga faza u kojoj će se cijepiti stariji od 65 godina i kronični bolesnici pa je to razlog što su do jučer liječnici obiteljske medicine trebali dostaviti županijskim zavodima za javno zdravstvo podatke o tom dijelu populacije o kojoj se i inače skrbe.
No, uskoro bi trebao slijediti i poziv građanima da se prijave za cijepljenje svojim liječnicima obiteljske medicine kako bi se također morao napraviti plan cijepljenja po ordinacijama s točnim brojem potrebnih doza.
 

Hrvatska je, zasad, rezervirala 4,5 milijuna doza, što bi trebalo biti dostatno za više od pola populacije.

Srbija je preko covax sistema obezbedila milion i 800 hiljada doza vakcine protiv korone, a prve će, najverovatnije, do kraja godine stići u našu zemlju, izjavio je predsednik Srbije Aleksandar Vučić u današnjem obraćanju javnosti.

At #WBIF steering committee meeting today I also confirmed that we are working on how to make #COVID19 vaccines available to the #WesternBalkans in a timely manner, as they start to be deployed in the #EU. We stand by our partners.

— Oliver Varhelyi (@OliverVarhelyi) December 10, 2020

Russia’s Sputnik V vaccine efficiency raised to 96.2%

The preliminary data obtained in the Russian Sputnik V coronavirus vaccine trials show that the efficiency of the jab stands at 69.3% after the first component is administered and 96.2% after the second, member of the independent monitoring committee examining the results of the vaccine’s clinical trials Ramil Khabriyev said Thursday.

Earlier, the Russian Direct Investment Fund (RDIF) reported that the coronavirus vaccine is 95% effective.

"The assessment was conducted in the period between the 14th and the 21st day, or before the injection of the second component, while the second observation group is after the second component is administered. So, if we compare or assess the efficiency as of today, it is calculated and submitted to us, developers and researchers, to be 96.2%," he said at a scientific forum.
...

kapetanm wrote:Na kraju dve trećine planete ješće limun i ispijati čajeve, ne mogu da zamislim složeni transport vakcine na -70 stepeni kroz Indiju ili Somaliju. Ionako je neće ni biti još par godina pa ko živ ko mrtav

Marius Lăcătuș wrote:

kapetanm wrote:Na kraju dve trećine planete ješće limun i ispijati čajeve, ne mogu da zamislim složeni transport vakcine na -70 stepeni kroz Indiju ili Somaliju. Ionako je neće ni biti još par godina pa ko živ ko mrtav

ne loži se - indija će imati svoju lokalizovanu proizvodnju vakcine koja ce biti kastomizirana za njihove uslove.

kapetanm wrote:Na kraju dve trećine planete ješće limun i ispijati čajeve, ne mogu da zamislim složeni transport vakcine na -70 stepeni kroz Indiju ili Somaliju. Ionako je neće ni biti još par godina pa ko živ ko mrtav

Serum Institute of India Pvt. Ltd. is now the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines.

The world’s largest vaccine manufacturer by volume is in a pact with the co-developer of the vaccine, British firm AstraZeneca plc. for manufacturing of about 1 billion doses of the vaccine and its distribution and sale in India and other low- and Middle-income countries.

DECEMBER 11, 202010:18 AM
UPDATED 8 HOURS AGO
AstraZeneca hitches ride with Russia's Sputnik in vaccine race

By Andrew Osborn, Pushkala Aripaka
5 MIN READ

(Reuters) - AstraZeneca is to start clinical trials to test a combination of its experimental COVID-19 vaccine with Russia’s Sputnik V shot to see if this can boost the efficacy of the British drugmaker’s vaccine, Russia’s sovereign wealth fund said on Friday.

Trials will start by the end of the year and Russia wants to produce the new vaccine jointly if it is proven to be effective, said the RDIF wealth fund, which has funded Sputnik V.

AstraZeneca said it was considering how it could assess combinations of different vaccines, and would soon begin exploring with Russia’s Gamaleya Institute, which developed Sputnik V, whether two vaccines based on a common-cold virus could be successfully combined.

It did not give further details. However, its Russian arm said it would start to enrol adults aged 18 and older for the trial.

The cooperation between one of Britain’s most valuable listed companies and the state-backed Russian research institute highlights the pressure to develop an effective shot to fight the pandemic, which has killed over 1.5 million people.

The move is likely to be seen in Moscow as a long-awaited vote of confidence by a Western manufacturer in Sputnik V, which the Russian defence ministry alleged on Friday was the target of a foreign-backed smear campaign.

Sputnik’s Russian developers say clinical trials, still under way, have shown it has an efficacy rate of over 90%, higher than that of AstraZeneca’s own vaccine and similar to those of U.S. rivals Pfizer and Moderna.

Some Western scientists have raised concerns about the speed at which Russia has worked, giving the regulatory go-ahead for its vaccines and launching large-scale vaccinations before full trials to test Sputnik V’s safety and efficacy have been completed. Russia says the criticism is unfounded.

AstraZeneca, once seen as a frontrunner in the vaccine race, is preparing further tests to confirm whether its shot could be 90% effective, potentially slowing its rollout.

Its average efficacy rate was 70.4% in interim late-stage data - which prompted the developers of Sputnik V to suggest trying to combine the two vaccines.

TWO VACCINES BETTER THAN ONE?

RDIF head Kirill Dmitriev called AstraZeneca’s acceptance of the proposal “an important step towards uniting efforts in the fight against the pandemic”.

Kate Bingham, chair of Britain’s vaccine task force, said this week that the UK would start trials next year using combinations of different kinds of vaccine for the initial and booster vaccinations, in the hope that a “mix-and-match” approach might maximise the immune response.

Both projects are using harmless adenoviruses as vehicles, or vectors, to carry genetic instructions into the body to prompt cells to produce antibodies, an approach that has previously been used in an Ebola vaccine.

One challenge of such a method is that the immune system could attack the vector and, in particular, neutralise the second booster shot that is now an important feature of the leading COVID-19 vaccine candidates.

Using different viral vectors for the two shots is one approach that researchers, including at the Gamaleya Institute, have pursued. Combining vaccines from different developers could be another.

AstraZeneca did not mention immunity against the viral vector as an issue in its statement on Friday.

The firm and its partner Oxford University have used a harmless adenovirus found only in monkeys to ensure that people receiving the shot had not previously been exposed to the vector and developed an immune response against it.

Russian officials have not always been complimentary about the British vaccine.

When AstraZeneca paused a clinical trial in September due to the unexplained illness of a volunteer, Kremlin spokesman Dmitry Peskov told reporters that Sputnik V was more reliable because it was based on an adenovirus found in humans, whereas the British candidate was a “monkey vaccine”.

The new partnership may draw scrutiny after Britain said in July that hackers backed by the Russian state were trying to steal COVID-19 vaccine and treatment research from academic and pharmaceutical institutions around the world. The Kremlin rejected the allegations.

Reporting by Pushkala Aripaka in Bengaluru and Andrew Osborn in Moscow; Additional reporting by Ludwig Burger; Writing by Josephine Mason; editing by Patrick Graham, Mark Potter and Kevin Liffey

The rules-based international order https://t.co/hGoWbJ9DjN

— Vincent Bevins (@Vinncent) December 12, 2020